DeepSee

Patient-derived microtumors (PDMs) and autologous immune cells will be isolated from fresh tumor tissue. PDM-immune cell co-cultures will be treated with chemo- and immunotherapeutics followed by single cell proteo-genomic analysis including custom algorithm generation to enable identification of treatment-induced changes of cellular PDM composition. Treated co-cultures will be characterized by flow cytometry, gene expression and cytokine analyses combined with next-generation sequencing based TCR analysis to re-identify TCRs prone to PDM infiltration. Bioinformatics tools including flow cytometry and drug-response data integration will be developed. A service for single cell PDM profiling including wet lab techniques and data analysis requirements will be jointly developed and commercialized.